Disc Medicine (IRON) said Monday that it presented data supporting the advancement of its three investigational drugs.
The company said phase 2 studies showed that its drug candidate bitopertin reduces protoporphyrin IX levels and improves symptoms in adults and adolescents with erythropoietic protoporphyria, a genetic condition that can lead to liver disease.
Updates from pre-clinical studies showed a combination of ruxolitinib with DISC-0974's mouse analog showed potential as a treatment for anemia in myelofibrosis and inflammatory bowel disease, according to the company.
The company also said that DISC-3405 reduced serum iron levels and was well-tolerated in healthy volunteers, suggesting potential for treating polycythemia vera and sickle cell disease.
Shares of the company were down 1.5% in recent trading.
Price: 63.88, Change: -0.94, Percent Change: -1.45
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.